Literature DB >> 17572452

Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function.

Kjell Fuxe1, Sergi Ferré, Susanna Genedani, Rafael Franco, Luigi F Agnati.   

Abstract

The dopamine D1 and D2 receptors are major receptors in the regulation of striatal function and striatal adenosine A1 and A2A receptors are major modulators of their signaling. The evidence suggests the existence of antagonistic A1-D1 heteromeric receptor complexes in the basal ganglia and prefrontal cortex and especially in the direct striatonigral-striatoentopeduncular GABA pathways. The neurochemical and behavioral findings showing antagonistic A1-D1 receptor interactions can be explained by the existence of such A1-D1 heteromeric receptor complexes and of antagonistic interactions at the level of the second messengers. In contrast, A2A-D2 receptor heteromers may exist in the dorsal and ventral striato-pallidal GABA pathways, where activation of A2A receptors reduces D2 receptor recognition, coupling and signaling. As a result of the A2A receptor-induced reduction of D2 receptor signaling, the activity of these GABA neurons is increased resulting in reduced motor and reward functions mediated via the indirect pathway, causing a reduced glutamate drive to the prefrontal and motor areas of the cerebral cortex. Thus, A2A receptor antagonists and A2A receptor agonists, respectively, may offer novel treatments of Parkinson's disease (reduced D2 receptor signaling) and of schizophrenia and drug addiction (increased D2 receptor signaling).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17572452     DOI: 10.1016/j.physbeh.2007.05.034

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  95 in total

1.  Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion.

Authors:  Jayms D Peterson; Joshua A Goldberg; D James Surmeier
Journal:  Neurobiol Dis       Date:  2011-09-10       Impact factor: 5.996

Review 2.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 3.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 4.  Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.

Authors:  K Fuxe; M Canals; M Torvinen; D Marcellino; A Terasmaa; S Genedani; G Leo; D Guidolin; Z Diaz-Cabiale; A Rivera; L Lundstrom; U Langel; J Narvaez; S Tanganelli; C Lluis; S Ferré; A Woods; R Franco; L F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

Review 5.  The A(2A)-adenosine receptor: a GPCR with unique features?

Authors:  J Zezula; M Freissmuth
Journal:  Br J Pharmacol       Date:  2008-02-04       Impact factor: 8.739

6.  Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.

Authors:  John D Salamone; Andrew M Farrar; Laura Font; Vatsal Patel; Devra E Schlar; Eric J Nunes; Lyndsey E Collins; Thomas N Sager
Journal:  Behav Brain Res       Date:  2009-03-03       Impact factor: 3.332

7.  The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists.

Authors:  Lila T Worden; Mona Shahriari; Andrew M Farrar; Kelly S Sink; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2008-12-02       Impact factor: 4.530

Review 8.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

9.  ADORA2A Gene variation, caffeine, and emotional processing: a multi-level interaction on startle reflex.

Authors:  Katharina Domschke; Agnieszka Gajewska; Bernward Winter; Martin J Herrmann; Bodo Warrings; Andreas Mühlberger; Katherina Wosnitza; Evelyn Glotzbach; Annette Conzelmann; Andrea Dlugos; Manfred Fobker; Christian Jacob; Volker Arolt; Andreas Reif; Paul Pauli; Peter Zwanzger; Jürgen Deckert
Journal:  Neuropsychopharmacology       Date:  2011-10-19       Impact factor: 7.853

10.  Nucleus tractus solitarii A(2a) adenosine receptors inhibit cardiopulmonary chemoreflex control of sympathetic outputs.

Authors:  Zeljka Minic; Donal S O'Leary; Tadeusz J Scislo
Journal:  Auton Neurosci       Date:  2013-10-25       Impact factor: 3.145

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.